Skip to content
OpenCapital
Get started

Profound Medical PROF EBIT

EBIT at other companies

TriSalus Life Sciences, Inc. logo
TriSalus Life Sciences, Inc.TLSI
-$8.41M-14.8%
Bioventus logo
BioventusBVS
$8.42M+72.8%
Intuitive Surgical logo
Intuitive SurgicalISRG
——

Other financials

Income statement

See full
Revenue$5.3M+104%
Gross profit$3.8M+107%
Operating income-$8.0M+28.2%
Net income-$7.1M+34.2%
EPS (diluted)$0.19-47.2%

Balance sheet

See full
Cash & equivalents$50.3M+8.3%
Total debt$7.5M+52.8%
Total equity$59.4M+17.0%
Total assets$73.5M+20.7%

Cash flow

See full
Operating cash flow-$8.6M-3.6%
CapEx$44.0K—
Free cash flow-$9.6M—

Valuation

See full
Market cap$241.65M+30.7%
Enterprise value$198.81M+28.7%
P/S12.8×-2.8×

Profitability

See full
Gross margin71.1%+3.4pp
Operating margin-202.6%-51.3pp
Net margin-206.8%-39.0pp
FCF margin-238.4%—

Returns & leverage

See full
Return on equity-70.6%+4.8pp
Debt / equity0.1×0.0×
Current ratio6.6×-4.8×

Where this comes from

Calculated from Profound Medical’s reported figures.

−$8.0Moperating income−$7.0Mincome before tax+$377.0Kinterest expense=-$8.02M

The official record: Profound Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Profound Medical's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Profound Medical's EBIT?
Profound Medical (PROF) reported EBIT of -$8.02M in Q1 2026.
How has Profound Medical's EBIT changed year-over-year?
Profound Medical's EBIT increased by 28.2% year-over-year, from -$11.17M to -$8.02M.
What is the long-term trend for Profound Medical's EBIT?
Over 2 years (2023 to 2025), Profound Medical's EBIT has grown at a 20.0% compound annual growth rate (CAGR), from -$28.65M to -$41.25M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.